The Opportunity
“How can we generate translationally relevant data to assess the therapeutic potential of a novel MMP13 inhibitor in aortic aneurysm prevention?”

Boehringer Ingelheim was advancing a promising compound targeting MMP13, a matrix metalloproteinase implicated in aortic aneurysm progression. To support pipeline decision-making, the company sought to conduct a scientifically rigorous and clinically meaningful preclinical trial, with a strong focus on translational value and internal alignment with regulatory expectations.

Laura’s Role
Boehringer Ingelheim partnered with Laura to lead the full preclinical development effort—from experimental design and in vivo model selection to data interpretation and scientific dissemination. Drawing on her deep expertise in ECM biology and cardiovascular pathology, Laura introduced advanced screening methodologies such as echocardiography for real-time aneurysm monitoring. She also ensured that the study met regulatory and internal scientific standards, providing strategic guidance throughout the 5-year project.

The Outcome
The study delivered high-quality, in vitro and in vivo data that directly supported internal development decisions and laid the groundwork for potential clinical translation. The impact of the work was amplified through global scientific engagement, with Laura presenting the findings in a widely attended industry webinar. The project exemplifies how expert-led preclinical strategy can accelerate innovation and align research execution with long-term therapeutic objectives.